Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA

Barnaby Hunt; Michelle Mocarski; William J. Valentine; Jakob Langer

首页> 外文期刊>Advances in therapy. >Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA

【24h】

Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA

机译：误解：评估IDEGLIRA的短期成本效益与美国2型糖尿病患者的胰岛素狼蛛U100的持续上升滴定

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Advances in therapy.》 |2017年第6期|共2页
作者
Barnaby Hunt; Michelle Mocarski; William J. Valentine; Jakob Langer;
展开▼
作者单位

Ossian Health Economics and Communications;

Novo Nordisk Inc.;

Ossian Health Economics and Communications;

Novo Nordisk A/S;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA [J] . Barnaby Hunt, Michelle Mocarski, William J. Valentine, Advances in therapy. . 2017,第6期

机译：误解：评估IDEGLIRA的短期成本效益与美国2型糖尿病患者的胰岛素狼蛛U100的持续上升滴定
2. The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): A short‐term cost‐effectiveness analysis in the UK setting [J] . Drummond Russell, Malkin Samuel, Du Preez Michelle, Diabetes, obesity & metabolism . 2018,第10期

机译：2型糖尿病患者的糖尿病患者组合胰岛素Degludec / Liraglutide（IDEGLIRA）与基础推注疗法（胰岛素冰柱U100加胰岛素Aspart）：英国环境中的短期成本效益分析
3. Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia [J] . Neboj?a Lali?, Monika Russel-Szymczyk, Marina Culic, Diabetes therapy . 2018,第3期

机译：胰岛素解毒剂与胰岛素甘精胰岛素U100在塞尔维亚1型和2型糖尿病患者中的成本效果
4. Switching to insulin glargine 300 U/mL from other basal insulin analogues provides less 24-hour glucose variability in hospitalized patients with type 1 diabetes [C] . V.V. Klimontov, E.A. Koroleva, O.N. Fazullina International Multiconference Bioinformatics of Genome Regulation and StructureSystems Biology . 2018

机译：从其他基础胰岛素类似物转换为甘精胰岛素300 U / mL可使住院的1型糖尿病患者的24小时葡萄糖变异性降低
5. Incidence of hypoglycemia and associated costs in Type 1and Type 2 diabetes patients treated with insulin analogs vs. human insulin: A retrospective cohort study. [D] . Shah, Hiren P. 2014

机译：使用胰岛素类似物与人胰岛素治疗的1型和2型糖尿病患者的低血糖发生率和相关费用：一项回顾性队列研究。
6. Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA [O] . Barnaby Hunt, Michelle Mocarski, William J. Valentine, -1

机译：勘误到：在美国2型糖尿病患者中IDegLira的短期成本效果与持续增加胰岛素甘精胰岛素U100的评价
7. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA [O] . Barnaby Hunt, Michelle Mocarski, William J. Valentine, 2017

机译：美国2型糖尿病患者IDegLira的短期成本效果评价与持续升糖甘精胰岛素U100的比较

Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA

著录项

相似文献

相关主题

期刊订阅